Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/81464
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Treatment technique evolution and dosimetry trends over seven years of low dose rate prostate brachytherapy at an Australian institution
Author: Rutten, T.
Lawson, J.
Marcu, L.
Citation: Physica Medica, 2013; 29(6):662-669
Publisher: Istituti Editoriali E Polgrafici Internazionali
Issue Date: 2013
ISSN: 1120-1797
1724-191X
Statement of
Responsibility: 
Thomas P. Rutten, John M. Lawson, Loredana G. Marcu
Abstract: Low dose rate prostate brachytherapy treatments began at the Royal Adelaide Hospital (RAH), Australia, in September 2004. This paper will focus on the evolution of treatment technique since then showing how procedural improvements have enabled timely diagnosis of under-dose and scheduling of top-up treatments for sub-optimum implants, and how significant time savings have been achieved for staff and patients. In addition, implant dosimetry trends over this period have been investigated and results are presented. Iodine-125 seeds (Oncura model 6711) have been used since LDR prostate treatments began, with an aim to deliver a prostate dose of 145 Gy. Three key changes in implant technique took place during the period Sept 2004 to Sept 2011. The live implant dosimetry trends of the prostate D90, urethra V150, and rectum D0.1cc and D2.0cc, were assessed to see if the change in technique had an impact on the treatment planning and seed deployment. The switch from manual loading of seeds to pre-loaded needles and the change from a two-step pre-planning procedure to live planning have realized the greatest time savings with approximately 1.0 FTE physicist day saved per 2 patient implant day and 2 patient visits saved per treatment. Dosimetric parameters also improved with mean implant D90s rising from 166 Gy to 180 Gy. The average Urethra D10 also increased over the study group, rising from 186 Gy to 199 Gy while the rectum dose remained unchanged. Both rectum and urethra dose remained below GEC-ESTRO guidelines despite the observed rise in urethral dose.
Keywords: Prostate; Brachytherapy; I-125; Dosimetry
Rights: Copyright © 2012 Associazione Italiana di Fisica Medica
RMID: 0020132569
DOI: 10.1016/j.ejmp.2012.07.004
Appears in Collections:Physics publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.